Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
394 stopped studies mapped to Hepatocellular Carcinoma and descendants · 93% state a reason
Over the 394 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03008512 | A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After… | Phase 2 | terminated | Jan 2, 2017 | Gachon University Gil Medical Center | Poor accrual | Enrollment / accrual |
| NCT02524119 | LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma(LEE001) | Phase 2 | terminated | Aug 14, 2015 | University of Texas Southwestern Medical Center | This study was terminated after the sponsor withdrew our support | Other (stated, no rule matched) |
| NCT03219372 | Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence | Phase 2 | terminated | Jul 17, 2017 | Cedars-Sinai Medical Center | Study discontinued due to low accrual. | Enrollment / accrual |
| NCT00823290 | Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) | Phase 1 | terminated | Jan 15, 2009 | University of Erlangen-Nürnberg Medical School | Investigator left site | Investigator |
| NCT00503867 | SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma | N/A | terminated | Jul 19, 2007 | Sirtex Medical | Low patient recruitment | Enrollment / accrual |
| NCT03040453 | Immunological Response After Ablative Therapy in the Liver(IRAL) | N/A | withdrawn | Feb 2, 2017 | Karolinska Institutet | poor recruitment | Enrollment / accrual |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | Phase 1 | withdrawn | Feb 17, 2020 | Jiujiang University Affiliated Hospital | Study is withdrawn because of administrative reasons | Other (stated, no rule matched) |
| NCT02558205 | Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry | — | withdrawn | Sep 23, 2015 | Rush University Medical Center | unable to rectuir | Other (stated, no rule matched) |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With…(TRAP) | Phase 1 | terminated | Jan 8, 2014 | Polaris Group | not stated | Not stated |
| NCT04044326 | The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant… | N/A | withdrawn | Aug 5, 2019 | National Taiwan University Hospital | Machine cannot provide | Other (stated, no rule matched) |
| NCT04546802 | HepATocellular Cancer Hcv Therapy Study(HATCHeT) | Phase 3 | withdrawn | Sep 14, 2020 | Bayside Health | Recruitment will be too difficult due to available PBS funded treatment and recent Australian… | Enrollment / accrual |
| NCT03203837 | Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere® | — | terminated | Jun 29, 2017 | Northwestern University | Funding Discontinued due to low accrual rate | Enrollment / accrual |
| NCT03644511 | Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent…(SORAGO-HCC) | — | terminated | Aug 23, 2018 | Bayer | The interest of potential centers is very limited. | Other (stated, no rule matched) |
| NCT03172559 | Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not…(RADBRI) | N/A | withdrawn | Jun 1, 2017 | University Health Network, Toronto | Investigator decided not to pursue the study due to other competing studies. | Investigator |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | Phase 1 | terminated | Apr 27, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04395118 | STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs(STOP-HCC) | N/A | withdrawn | May 20, 2020 | University of Texas Southwestern Medical Center | Study will not be conducted as a RCT due to limited project timeline. | Other (stated, no rule matched) |
| NCT02989870 | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | Phase 1 | withdrawn | Dec 12, 2016 | H. Lee Moffitt Cancer Center and Research Institute | No Interest. Investigator was unable to enroll any participants on study. | Investigator |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by… | Phase 1 / Phase 2 | terminated | Mar 29, 2018 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT04093648 | T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor… | Phase 1 | withdrawn | Sep 18, 2019 | Baylor College of Medicine | The key elements of this study were incorporated into another study. | Other (stated, no rule matched) |
| NCT01486134 | Major RF Ablations of Hepatomas Under MR Thermometry Monitoring(ARMTICH) | N/A | terminated | Dec 6, 2011 | Assistance Publique - Hôpitaux de Paris | For technical reasons | Other (stated, no rule matched) |
| NCT02013778 | Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC | Phase 1 / Phase 2 | terminated | Dec 17, 2013 | Abramson Cancer Center at Penn Medicine | Lack of enrollment | Enrollment / accrual |
| NCT03748927 | Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma | — | withdrawn | Nov 21, 2018 | National Cancer Institute (NCI) | slow/insufficient accrual | Enrollment / accrual |
| NCT03990974 | Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC…(HCC) | Phase 3 | suspended | Jun 19, 2019 | Sun Yat-sen University | There were difficulties in implementation | Other (stated, no rule matched) |
| NCT04025567 | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral | Phase 2 | withdrawn | Jul 19, 2019 | National Cancer Institute (NCI) | slow/insufficient accrual. | Enrollment / accrual |
| NCT01760616 | Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical… | Phase 4 | terminated | Jan 4, 2013 | Qidong Gaitianli Medicines Co., Ltd | difficult to recruit patients | Enrollment / accrual |
| NCT03079778 | Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy…(TACERT) | N/A | withdrawn | Mar 14, 2017 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Opened up a separate Clinicaltrials.gov trial form, study ID TACE | Other (stated, no rule matched) |
| NCT02580253 | Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay… | Phase 2 | withdrawn | Oct 20, 2015 | Zhejiang University | no patients enrolled | Enrollment / accrual |
| NCT02867280 | Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion… | Phase 3 | terminated | Aug 15, 2016 | Sun Yat-sen University | Midterm analysis showed negative results. | Other (stated, no rule matched) |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell… | Phase 1 | withdrawn | Jul 14, 2017 | National Cancer Institute (NCI) | Other - Drug Manufacturer decision to close study | Drug supply |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | Phase 1 / Phase 2 | withdrawn | Aug 15, 2013 | Mirror Biologics, Inc. | interventional radiologist suffered stroke and unable to perform RFA procedure | Other (stated, no rule matched) |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | Phase 1 / Phase 2 | withdrawn | Nov 26, 2013 | Mirror Biologics, Inc. | Study site change to Thailand | Other (stated, no rule matched) |
| NCT02289300 | A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver… | Phase 2 | withdrawn | Nov 13, 2014 | A2 Healthcare Taiwan Corporation | At sponsor's discretion | Other (stated, no rule matched) |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With… | Phase 2 / Phase 3 | withdrawn | Aug 5, 2019 | Shi Ming | Bristol-Myers Squibb company terminated this study | Sponsor / business decision |
| NCT03382886 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular…(NUANCE) | Phase 1 | terminated | Dec 26, 2017 | University of Utah | PI decided to terminate due to low/slow accrual | Enrollment / accrual |
| NCT03433703 | Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following… | Phase 2 | terminated | Feb 14, 2018 | Eisai Inc. | Study recruitment was stopped due to difficulty in enrolling the targeted number of participants. | Enrollment / accrual |
| NCT02288507 | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With… | Phase 1 | withdrawn | Nov 11, 2014 | University of Hawaii | Closed due to no accrual | Enrollment / accrual |
| NCT02323360 | A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment… | N/A | terminated | Dec 23, 2014 | Istituto Clinico Humanitas | too slow enrollment | Enrollment / accrual |
| NCT03738111 | Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma | Phase 1 | withdrawn | Nov 13, 2018 | Lee's Pharmaceutical Limited | Sponsor's commercial decision | Other (stated, no rule matched) |
| NCT02147301 | TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve | N/A | terminated | May 26, 2014 | University of California, San Francisco | Risk to benefit ratio is not acceptable | Other (stated, no rule matched) |
| NCT02946138 | Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of… | Phase 2 | withdrawn | Oct 27, 2016 | Shanghai Proton and Heavy Ion Center | enrollment was too slow | Enrollment / accrual |
| NCT01817205 | Combined Chemoembolization and Systemic Hyperthermia for Unresectable Hepatocellular… | N/A | terminated | Mar 25, 2013 | Chinese University of Hong Kong | poor case accrual | Enrollment / accrual |
| NCT01806740 | DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients…(DCE-MRI) | Phase 4 | terminated | Mar 7, 2013 | Guerbet | The planned number of enrolled patients was not reached. | Enrollment / accrual |
| NCT01465464 | Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With…(ORIENTAL) | Phase 3 | terminated | Nov 4, 2011 | Taiho Pharmaceutical Co., Ltd. | not stated | Not stated |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Phase 2 | terminated | Oct 24, 2017 | Effector Therapeutics | The study was terminated due to change in focus of the development program | Other (stated, no rule matched) |
| NCT03349255 | Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma | Phase 1 | terminated | Nov 21, 2017 | Aeon Therapeutics (Shanghai) Co., Ltd. | Will study new T-cell construct for the same indication | Other (stated, no rule matched) |
| NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin…(LD-FOX4/HCC) | Phase 2 / Phase 3 | withdrawn | Aug 19, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT02534337 | Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for… | Phase 2 / Phase 3 | withdrawn | Aug 27, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT02584556 | Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy… | Phase 2 / Phase 3 | withdrawn | Oct 22, 2015 | Guangxi Medical University | not stated | Not stated |
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for… | Phase 2 / Phase 3 | withdrawn | Oct 23, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT03919383 | Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | Phase 2 | withdrawn | Apr 18, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 4, 2021source: clinicaltrials